Astellas acquisition of Audentes: Japanese pharma company Astellas Pharma has agreed to acquire US gene therapy company Audentes Therapeutics in an all-cash deal worth about $3 billion, as per pharma acquisition news. Based in California, Audentes Therapeutics calls itself a clinical-stage company focused on developing a portfolio of Adeno-associated virus (AAV)-based genetic medicines for the […]
US biopharma company Catabasis Pharmaceuticals has wrapped up enrollment for the phase 3 PolarisDMD clinical trial designed to evaluate edasalonexent, an NF-kB inhibitor, in Duchenne muscular dystrophy (DMD). The biopharma company said that the target enrollment of 125 boys was surpassed owing to strong interest from its 40 clinical sites across eight countries along with […]
Pfizer, the US pharmaceutical giant, has announced the discontinuation of two ongoing clinical trials for its drug domagrozumab (PF-06252616), intended to treat Duchenne muscular dystrophy (DMD). This decision comes after the trials failed to meet primary efficacy endpoints. The trials, identified as B5161002 and B5161004, were designed to evaluate the safety and efficacy of domagrozumab, […]
US based Exonics Therapeutics has secured $5 million seed funding from CureDuchenne Ventures, a subsidiary of nonprofit DMD advocacy group, CureDuchenne to advance its therapy for Duchenne Muscular Dystrophy, a severe form of muscular dystrophy.
Exonics Therapeutics, a biotechnology firm based in Boston, Massachusetts, has secured $5 million in seed funding from CureDuchenne Ventures, a subsidiary of the nonprofit Duchenne Muscular Dystrophy (DMD) advocacy group, CureDuchenne. This funding is aimed at further developing gene editing technologies, including CRISPR/Cas9, to potentially offer a curative therapy for Duchenne Muscular Dystrophy, a severe […]